Skip to content
Menu

Leerink Partners Upgrades Abbott Laboratories to Outperform, Announces $124 Price Target

Benzinga Newsdesk 8 hours ago

Analyst RatingsNewsUpgradesPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Leerink Partners analyst Mike Kratky upgrades Abbott Laboratories (NYSE:ABT) from Market Perform to Outperform and announces $124 price target.

Leerink Partners analyst Mike Kratky upgrades Abbott Laboratories (NYSE:ABT) from Market Perform to Outperform and announces $124 price target.

Read at benzinga.com